company background image
AMRN logo

Amarin NasdaqGM:AMRN Stock Report

Last Price

US$0.87

Market Cap

US$358.0m

7D

-14.5%

1Y

-35.9%

Updated

18 Apr, 2024

Data

Company Financials +

Amarin Corporation plc

NasdaqGM:AMRN Stock Report

Market Cap: US$358.0m

AMRN Stock Overview

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates.

AMRN fundamental analysis
Snowflake Score
Valuation6/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Amarin Corporation plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amarin
Historical stock prices
Current Share PriceUS$0.87
52 Week HighUS$1.49
52 Week LowUS$0.65
Beta2.01
1 Month Change0.50%
3 Month Change-16.97%
1 Year Change-35.90%
3 Year Change-83.20%
5 Year Change-95.44%
Change since IPO-99.85%

Recent News & Updates

Amarin Corporation: Small Signs Of Recovery May Not Be Enough

Apr 16

Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding

Mar 12
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding

Recent updates

Amarin Corporation: Small Signs Of Recovery May Not Be Enough

Apr 16

Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding

Mar 12
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding

Amarin: Sarissa Is Giving Me Hope Again

Jan 15

Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified

Jan 03
Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified

Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)

Nov 19
Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)

Investors Don't See Light At End Of Amarin Corporation plc's (NASDAQ:AMRN) Tunnel

Sep 27
Investors Don't See Light At End Of Amarin Corporation plc's (NASDAQ:AMRN) Tunnel

We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth

Jul 18
We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth

Is Amarin (NASDAQ:AMRN) In A Good Position To Deliver On Growth Plans?

Nov 11
Is Amarin (NASDAQ:AMRN) In A Good Position To Deliver On Growth Plans?

Amarin gains as activist Sarissa starts process for special meeting to replace some board members

Oct 11

Amarin down 21% on higher than normal daily volume

Aug 22

For Amarin, Something Wishful This Way Comes

Aug 14

Amarin Q2 2022 Earnings Preview

Aug 02

HLS Therapeutics gets reimbursement for Vascepa in Ontario

Jul 25

Amarin's Vazkepa medicine gets final guidance from UK body for reimbursement and use

Jul 13

Amarin extends losses after Stat report on cardiovascular therapy

Jun 30

Amarin: Alex Denner, Health Net, Statin Combo, And Signs Of Better Times

Apr 19

Here's Why We're Not At All Concerned With Amarin's (NASDAQ:AMRN) Cash Burn Situation

Feb 23
Here's Why We're Not At All Concerned With Amarin's (NASDAQ:AMRN) Cash Burn Situation

Shareholder Returns

AMRNUS BiotechsUS Market
7D-14.5%-4.7%-3.7%
1Y-35.9%-2.7%20.2%

Return vs Industry: AMRN underperformed the US Biotechs industry which returned -2% over the past year.

Return vs Market: AMRN underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is AMRN's price volatile compared to industry and market?
AMRN volatility
AMRN Average Weekly Movement11.7%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: AMRN's share price has been volatile over the past 3 months.

Volatility Over Time: AMRN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1989275Pat Holtwww.amarincorp.com

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers.

Amarin Corporation plc Fundamentals Summary

How do Amarin's earnings and revenue compare to its market cap?
AMRN fundamental statistics
Market capUS$358.02m
Earnings (TTM)-US$59.11m
Revenue (TTM)US$306.91m

1.2x

P/S Ratio

-6.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AMRN income statement (TTM)
RevenueUS$306.91m
Cost of RevenueUS$102.14m
Gross ProfitUS$204.77m
Other ExpensesUS$263.88m
Earnings-US$59.11m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 01, 2024

Earnings per share (EPS)-0.14
Gross Margin66.72%
Net Profit Margin-19.26%
Debt/Equity Ratio0%

How did AMRN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.